Experimental cocktail targets aggressive lymphoma in early trial
NCT ID NCT03321643
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 38 times
Summary
This early-phase trial is testing a combination of the immunotherapy drug atezolizumab, two chemotherapy drugs (gemcitabine and oxaliplatin), and the targeted antibody rituximab in 24 patients with transformed diffuse large B-cell lymphoma that has come back or stopped responding to treatment. The main goals are to check safety and find the best dose. The hope is that this mix of drugs can boost the immune system to fight the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (immunotherapy) combined with gemcitabine, oxaliplatin (chemotherapy), and rituximab (targeted antibody)
What this could lead to
If successful, this could point toward a new treatment option for patients with transformed diffuse large B-cell lymphoma that has relapsed or not responded to prior therapy.
What could go wrong
This is a very early (Phase I) pilot study with only 24 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness, and combination therapies often carry higher risk of side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.